Cartesian Therapeutics Inc.
$ 8.85
1.03%
07 Aug - close price
- Market Cap 267,760,000 USD
- Current Price $ 8.85
- High / Low $ 8.95 / 8.62
- Stock P/E N/A
- Book Value -5.19
- EPS -5.84
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -70.29 %
- 52 Week High 12.25
- 52 Week Low 5.60
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$34.57
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-04-30 | 2026-03-09 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-07 | 2023-11-13 |
| Reported EPS | 0.46 | -0.95 | -2.7065 | -0.73 | 0.5 | -0.65 | -0.5935 | -0.42 | 0.64 | -0.8 | -0.07 | -0.06 |
| Estimated EPS | -0.83 | -0.7 | -0.79 | -0.63 | -0.76 | -0.71 | -0.8257 | -0.55 | -0.09 | -1.42 | -0.04 | -0.06 |
| Surprise | 1.29 | -0.25 | -1.9165 | -0.1 | 1.26 | 0.06 | 0.2322 | 0.13 | 0.73 | 0.62 | -0.03 | 0 |
| Surprise Percentage | 155.4217% | -35.7143% | -242.5949% | -15.873% | 165.7895% | 8.4507% | 28.1216% | 23.6364% | 811.1111% | 43.662% | -75% | 0% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNAC
2026-08-07 19:40:50
Cartesian Therapeutics reported research and development expenses of $20.4 million for the second quarter. This financial detail is a key indicator of the company's investment in its pipeline and future growth. The article focuses solely on this financial reporting without further elaboration.
2026-08-07 19:40:50
Cartesian Therapeutics (NASDAQ: RNAC) has granted stock options for an aggregate of 115,250 common shares to four new employees, with grant dates of August 3 and August 6, 2026. These options have an exercise price equal to the closing Nasdaq Global Market price on the grant dates and will vest over four years, with full vesting by August 2030. The awards were made under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved under Nasdaq Rule 5635(c)(4) as a material employment inducement.
2026-08-06 14:48:00
Cartesian Therapeutics, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net income of $15.77 million. However, for the six-month period, the company posted a net loss of $23.41 million, a significant increase from the previous year's loss, and a substantial decrease in revenue.
2026-08-06 12:12:52
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 revenue of $0, with a diluted EPS of $0.46. The company experienced an increase in R&D spending due to the advancement of its Phase 3 AURORA trial, which widened its operating loss. However, a significant fair-value gain on contingent value rights kept its net income positive, and Cartesian projects its current cash resources will support operations into 2028.
2026-08-06 11:12:52
Cartesian Therapeutics reported its Q2 2026 financial results, including $149.3 million in cash and a net income of $15.8 million. The company announced that its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis is on track, with data expected in Q1 2027 and a BLA filing in mid-2027. Additionally, Cartesian secured up to $150 million in non-dilutive financing, extending its operational runway into 2028.
2026-08-06 11:12:52
Cartesian Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical pipeline and an extended cash runway into 2028. Key advancements include the Phase 3 AURORA trial for myasthenia gravis, a new strategic partnership with WestGene for an in vivo CAR-T platform, and ongoing Phase 2 and 1/2 trials for myositis and juvenile dermatomyositis, respectively. The company secured up to $150 million in non-dilutive financing, bolstering its financial position ahead of four anticipated clinical data readouts over the next year.
